Loop diuretics in the management of acute renal failure: a prospective, double-blind, placebo-controlled, randomized study
| Autor: | I. R. Shilliday, M. E. M. Allison, K. J. Quinn |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Adult
Male medicine.medical_specialty medicine.drug_class medicine.medical_treatment Urology Placebos Double-Blind Method Furosemide Oliguria medicine Humans Prospective Studies Diuretics Aged Sulfonamides Transplantation Kidney business.industry Torsemide Acute Kidney Injury Middle Aged Loop diuretic medicine.disease Diuresis Surgery medicine.anatomical_structure Nephrology Creatinine Female Hemodialysis Diuretic medicine.symptom business Kidney disease medicine.drug |
| Zdroj: | Nephrology Dialysis Transplantation. 12:2592-2596 |
| ISSN: | 1460-2385 0931-0509 |
| DOI: | 10.1093/ndt/12.12.2592 |
| Popis: | perhaps ameliorate the progress of ARF in patients with acute oliguria is strong. The evidence for this Background. Studies on the role of loop diuretics in patients with acute renal failure (ARF ) are largely practice is poor. Most reported studies have been largely anecdotal, retrospective, non randomized or retrospective, anecdotal, and poorly controlled. We report the results of a prospective, randomized, uncontrolled [1‐9]. Theoretically, administration of loop diuretics placebo-controlled, double-blind study examining the eVect of loop diuretics on renal recovery, dialysis, and should reduce the energy requirements of the cells of the thick limb of the loop of Henle [10]. These drugs death in patients with ARF. Methods. Ninety-two patients with ARF were enrolled act by inhibiting the Na+/2Cl’/K+ pump in the luminal cell membrane resulting in a fall in transcellular into the study. All received intravenous dopamine, 2 mg/kg body weight/min throughout, 20% mannitol, sodium transport. Basal Na/K ATPase activity becomes unnecessary and the requirement of the cell 100 ml every 6 h for the first 3 days, and, in a doubleblind manner, either torasemide, frusemide, or placebo, for oxygen falls. Brezis et al. [11] have shown that reducing active transport with frusemide significantly 3m g/kg body weight i.v. every 6 h for 21 days or until renal recovery or death. reduces the damage to the thick ascending limb of Henle’s loop in the isolated perfused kidney. It is Results. Renal recovery, the need for dialysis, and death were no diVerent in the three groups. Patients therefore possible that loop diuretics might ‘protect’ the cells of the thick ascending limb during the hypoxia given a loop diuretic had a significant rise in urine flow rate in the first 24 h compared to placebo which accompanies hypotension and sepsis, frequent predisposing factors in ARF, by reducing the need for |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|